Articles by Caitlyn Fitzpatrick

Caitlyn Fitzpatrick is an Assistant Editor for MD Magazine. She covers news and other topics in pain management and infectious disease. She can be contacted by e-mail at cfitzpatrick@mdmag.com.

Latest Articles

When Do You Bring Up Palliative Care with Patients with Adult Congenital Heart Disease? VIDEO
  |  Caitlyn Fitzpatrick
It’s a discussion that even the most seasoned physicians might struggle with—when is it time to talk end-of-life care? Ami Bhatt, MD, director of the Adult Congenital Heart Disease Program at Massachusetts General Hospital (MGH) explained both sides of the debate for patients with adult congenital heart disease.
Why Is It Necessary to Create a Cardio-Obstetrics Team? VIDEO
  |  Caitlyn Fitzpatrick
Some women may have suffered with cardiovascular problems since birth while others don’t find out until pregnancy unmasks the condition. Doreen DeFaria Yeh, MD, discusses the importance of merging physicians from cardiology and obstetrics.
Direct Oral Anticoagulants vs. Warfarin for Reducing Stroke, Major Bleeding VIDEO
  |  Caitlyn Fitzpatrick
Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.
Evidence Adds to Cardiac Dangers from Ibuprofen, Diclofenac Use
  |  Caitlyn Fitzpatrick
NSAIDs may help a variety of painful conditions, but come with heart risks.
SGLT-2 Inhibitors Reduced All-Cause Mortality Better Than Other Type 2 Diabetes Treatments VIDEO
  |  Caitlyn Fitzpatrick
Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.
Europe Experiences 40% Increase in HIV, Tuberculosis Coinfection
  |  Caitlyn Fitzpatrick
While TB cases are decreasing, HIV/TB coinfection cases are on the rise.
EBBINGHAUS Trial Finds No Cognitive Issues Associated with Evolocumab VIDEO
  |  Caitlyn Fitzpatrick
Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.
Heart Failure Drug Shows Beneficial Metabolic Effects in PARADIGM-HF Trial VIDEO
  |  Caitlyn Fitzpatrick
Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, detailed study results for sacubitril/valsartan the first angiotensin receptor neprilysin inhibitor to be approved by the FDA for its indication.
VTE Outcomes with Rivaroxaban Revealed in EINSTEIN CHOICE Trial VIDEO
  |  Caitlyn Fitzpatrick
Paul Burton, MD, PhD, revealed results from the phase 3 EINSTEIN CHOICE trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia. The trial examined the use of rivaroxaban (Xarelto/Janssen) or aspirin as extended treatment in patients with VTE.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$